ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
29 announcements
KMP Sumesh Gandhi sold a total of 3,900 equity shares in three separate market transactions on September 7, 8, and 9, 2026.
Fermenta Biotech Limited signed an exclusive licence agreement with VIT Vellore to commercialize Vitamin B12 fortification technology for fermented foods, enhancing its product portfolio.
Director Prashant Nagre sold 44,000 shares of Fermenta Biotech Ltd via market sale. The transaction value is Rs.2.20 Crore.
Fermenta Biotech Limited received a credit rating upgrade from CARE Ratings. Long-term bank facilities were raised to 'CARE BBB+; Stable' and short-term to 'CARE A2'.
Fermenta Biotech Limited has re-appointed Ms. Rajeshwari Datla as a Non-Executive Non-Independent Director of the company, effective August 11, 2026.
Fermenta Biotech held its AGM and secured shareholder approval for resolutions including financial statements, dividend declaration, and director appointments. All seven resolutions were passed successfully.
Q1FY27 revenue flat sequentially at INR 126.2 crore. Human nutrition volume grew 18% QoQ, offsetting animal nutrition weakness. EBITDA stood at INR 22.4 crore (17.7% margin).
Fermenta Biotech reported Q1FY27 consolidated revenue of ₹126.2 crore, down 13% YoY. Net profit for the period stood at ₹9.5 crore amid a 40% fall in animal nutrition realisations.
Fermenta Biotech Ltd reported revenue from operations of ₹121.8 Cr (-10.6% YoY) and net profit of ₹9.5 Cr (-56.0% YoY) for Q1 FY27.
Fermenta Biotech Limited has scheduled a board meeting on August 11, 2026, to consider and approve the standalone and consolidated unaudited financial results.
Fermenta Biotech Limited is now listed and admitted to dealings on the National Stock Exchange of India (NSE) effective from August 04, 2026.
The company submitted its quarterly shareholding pattern for the period ending June 30, 2026, as required by SEBI regulations.
Fermenta Biotech has scheduled its 74th Annual General Meeting for August 11, 2026. Agenda items include dividend declaration and approval for a Rs. 100 Crore related party transaction.
Fermenta Biotech Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26.
Fermenta Biotech Limited has issued the notice for its 74th Annual General Meeting, scheduled to be held on August 11, 2026.
Fermenta Biotech Limited has filed its Annual Report for the financial year 2025-26. The company also announced its 74th Annual General Meeting scheduled for August 11, 2026.
Fermenta Biotech's subsidiary FESPL will issue equity shares to Aasava Management Services, diluting Fermenta's stake to 91.76%. FESPL thus ceases to be a wholly-owned subsidiary.
Fermenta Biotech clarified to BSE that recent share price movements are market-driven. The company confirmed no undisclosed material information or impending announcements exist.
Fermenta Biotech received FSSAI approval for its plant-based Vitamin D3 product. This regulatory greenlight supports its 'Make in India' initiative and nutrition self-reliance.
Fermenta Biotech Limited was ranked 7th nationwide among Great Place To Work’s Top 50 Mid-size Workplaces for 2026. The accolade highlights its strong employee‑first culture.
Fermenta Biotech Ltd applied to NSE for listing and trading of its equity shares. This move aims to enhance liquidity and investor access.
Fermenta Biotech delivered core revenue growth of 27% YoY in FY26, driven by Vitamin D3 segments, despite headline declines from a high real-estate base in FY25.
Fermenta Biotech reported ₹547.8 Crore FY26 consolidated revenue, up 14% YoY. Strong Vitamin D3 growth drove a 44% rise in EBITDA excluding real estate.
Fermenta Biotech granted 3,95,400 stock options to employees under its 2025 ESOP scheme. The move aims to incentivize personnel while the company seeks direct listing on NSE.
Fermenta Biotech Ltd reported revenue from operations of ₹121.6 Cr (-13.0% YoY) and net profit of ₹18.6 Cr (-44.1% YoY) for Q4 FY26.
Fermenta Biotech reported audited financial results for FY2026 and recommended a 75% final dividend. The board fixed August 5, 2026, as the record date for payment.
Fermenta Biotech scheduled a board meeting for May 26, 2026. Directors will consider FY26 audited financial results and a final dividend recommendation.
Fermenta Biotech Limited (BSE: 506414) confirmed it does not meet the criteria for a 'Large Corporate' entity for FY 2025-26. The company reported outstanding borrowings of ₹17.39 Crore as of March 31, 2026, which is below the regulatory threshold for mandatory debt market sourcing.
Fermenta Biotech Limited (506414) shares have been admitted to dealings on the National Stock Exchange (NSE) under the 'Permitted to Trade' category. Trading is effective from April 20, 2026, following NSE circular 0645/2026. This move enhances the stock's liquidity by providing an additional trading platform for investors.